A team, led by senior author Morris J. Birnbaum, MD, PhD, the Willard and Rhoda Ware Professor of Medicine, with the Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania, found that the diabetes drug metformin works in a different way than previously understood. Their research in mice found that metformin suppresses the liver hormone glucagon's ability to generate an important signaling molecule, pointing to new drug targets. The findings were published online this week in Nature.
For fifty years, one of the few classes of therapeutics effective in reducing the overactive glucose production associated with diabetes has been the biguanides, which includes metformin, the most frequently prescribed drug for type 2 diabetes. The inability of insulin to keep liver glucose output in check is a major factor in the high blood sugar of type 2 diabetes and other diseases of insulin resistance.
"Overall, metformin lowers blood glucose by decreasing liver production of glucose," says Birnbaum. "But we didn't really know how the drug accomplished that."
Despite metformin's success, its mechanism of action remained imperfectly understood. About a decade ago, researchers suggested that metformin reduces glucose synthesis by activating the enzyme AMPK. But this understanding was challenged by genetic experiments in 2010 by collaborators on the present Nature study. Coauthors Marc Foretz and Benoit Viollet from Inserm, CNRS, and Université Paris Descartes, Paris, found that the livers of mice without AMPK still responded to metformin, indicating that blood glucose levels were being controlled outside of the AMPK pathway.
Taking another look at how glucose is regulated normally, the team knew that when there is no food intake and glucose decreases, glucagon is secreted from the pancreas to signal the liver to produce glucose. They then asked if metformin works by stopping the glucagon cascade.
The Nature study describes a novel mechanism by which metformin antagonizes the action of glucagon, thus reducing fasting glucose levels. The team showed that metformin leads to the accumulation of AMP in mice, which inhibits an enzyme called adenylate cyclase, thereby reducing levels of cyclic AMP and protein kinase activity, eventually blocking glucagon-dependent glucose output from liver cells.
From this new understanding of metformin's action, Birnbaum and colleagues surmise that adenylate cyclase could be a new drug target by mimicking the way in which it is inhibited by metformin. This strategy would bypass metformin's affect on a cell's mitochondria to make energy, and possibility avoid the adverse side effects experienced by many people who take metformin, perhaps even working for those patients resistant to metformin.
University of Pennsylvania School of Medicine: http://www.uphs.upenn.edu/news/
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Instead of brooding over a failed relationship, psychologist advises a couple of aspirin and distancing oneself from the event
Brazilian researchers release thousands of mosquitoes infected with a bacteria that suppresses dengue fever into the environment in Rio de Janeiro.
Major food companies have cut trillions of calories, and studies show Americans are consuming fewer calories because of it. But some advocates think companies should do more to improve our diets.
The National Institutes of Health is providing $10 million to explore sex difference in disease, part of a move to boost female numbers in clinical trials
The World Health Organization warns of more than 20,000 cases by early November if help doesn't arrive quickly in West Africa. The CDC projects 1.4 million cases by late January.
When you're paid to hit people, it's not always easy to stop at the end of the work day—a fact the NFL has to reckon with, and fast
Is Democracy a key to better levels of health in a country? That's long been the belief, but we hear about some research that shows that isn't always the case.
You can learn a lot about people if you mess with their minds. Here are four infamous experiments in which psychologists gave in to unethical temptations
The number of people without enough to eat has fallen rapidly over the past 25 years, but sub-Saharan Africa and parts of Asia are still struggling
New research raises serious questions about how artificial sweeteners might affect our bodies, but let's keep our cool and just do more research